The record
| Class | neuroprotective |
|---|---|
| Also known as | EDR peptide, T-33 peptide, Glutamylaspartylarginine |
| Chain length | - |
| Molecular weight | 418.4 Da |
| Half-life | Short (tripeptides typically minutes to hours) |
| Route | SC preferred; oral also used |
| Studied for | Cognitive decline; Memory impairment; Circadian rhythm disorders; Neuroprotection |
| Research use | Anti-aging CNS research; Neurodegenerative disease models; Hypoxia protection studies |
| What has been shown | Neuroprotective effects in hypoxia; Cognitive function improvement; Reduces oxidative stress markers; Protects against prenatal hyperhomocysteinemia damage |
| How it works | Pinealon penetrates cell membranes and nuclear membranes to interact directly with DNA, regulating gene expression. Does not bind to cell surface or cytoplasmic receptors. Prevents ROS accumulation, suppresses ERK 1/2 activation, modulates cell cycle by activating proliferation pathways. Acts as an epigenetic regulator influencing transcription factors and protein synthesis in neuronal tissue. |
| Patent status | Russian patents |
| Regulatory status | research/supplement |
Blank = not established in the record. Nothing is estimated to fill a gap.
Where it is matched
- Nerve Support / Neuro-repair Environment (affection, 46%)
- Neuroprotection Signaling (affection, 63%)
- Sleep Optimization (affection, 30%)
- Circadian Rhythm Alignment (affection, 50%)
- Oxidative Stress Resilience (affection, 39%)
- Acetaminophen toxicity (illness, 30%)
- Antioxidant supplementation (illness, 30%)
- Circadian rhythm disorders (illness, 100%)
- Cognitive decline (illness, 100%)
- Detoxification support (illness, 30%)
- Memory impairment (illness, 100%)
- Neuroprotection (illness, 100%)
- Skin lightening (illness, 30%)
- Poor sleep (symptom, 33%)
- Fatigue or low energy (symptom, 33%)